Light-emitting diode (DIRIGÉ) phototherapy has moved from clinical dermatology into mainstream professional beauty and at-home skincare. Yet behind every LED face mask, panneau, or handheld device sits a single, decisive engineering choice: longueur d'onde. The nanometer (nm) value printed on a spec sheet is not a marketing number — it determines how deep the light penetrates, which cellular pathways it activates, and whether a device qualifies for medical clearance such as FDA 510(k).
This reference article explains the ten clinically studied wavelengths used across modern LED therapy devices, the peer-reviewed evidence behind each, and what FDA 510(k) clearance — including the recently issued K250830 — actually means for brands sourcing OEM/ODM products. It is written for product managers, regulatory teams, distributeurs, and aesthetic professionals who need a working command of the science, not marketing claims.
1. The Science: How LED Light Interacts With Skin
LED phototherapy — also known as photobiomodulation (PBM) ou luminothérapie de faible intensité (Lllt) — works through non-thermal photon absorption. When a photon of the correct wavelength is absorbed by a chromophore inside skin tissue (most importantly cytochrome c oxidase in the mitochondrial respiratory chain), it triggers a cascade of intracellular events: increased ATP synthesis, modulated reactive oxygen species (ROS), and altered gene expression related to inflammation, prolifération, and extracellular matrix remodeling.1
Three principles govern every wavelength decision in LED device design:
- Absorption specificity — different chromophores (porphyrins, mélanine, hémoglobine, eau, cytochrome c oxydase) absorb light at characteristic peaks.
- Profondeur de pénétration — longer wavelengths in the red and near-infrared (Nir) range penetrate deeper into the dermis and subcutaneous tissue than shorter blue wavelengths.2
- Dose response — biological effects follow a biphasic dose curve: too little energy produces no effect, while excessive energy can inhibit the desired response.
These three principles are why wavelength selection cannot be improvised. Each nanometer range is matched to a specific clinical objective.
2. Wavelength-by-Wavelength: What the Evidence Actually Shows
415 nm — Blue-Violet (Antibactérien, Acné)
Le 415 nm band is absorbed by endogenous porphyrins (primarily coproporphyrin III) produced by Cutibactérie acnés (anciennement Propionibacterium acnes). Absorption generates singlet oxygen that disrupts the bacterium from within, producing a non-antibiotic antimicrobial effect.3 Clinical trials of 415 nm monotherapy and 415 nm + 633 nm combination protocols have demonstrated significant reductions in inflammatory acne lesion counts over 4–12 weeks.4 5 UN 2019 systematic review in Annals of Family Medicine concluded that blue-light phototherapy is a clinically viable adjunct for mild-to-moderate acne vulgaris.6
Pénétration: ~1 mm (epidermis and upper papillary dermis only).
460 nm — Blue (Sebum Regulation, Anti-Inflammation)
Slightly longer than 415 nm, 460 nm penetrates marginally deeper while retaining antibacterial properties. It is often used for sebum regulation and as a calming wavelength for inflamed skin. Because both 415 nm et 460 nm fall within the visible blue range, devices intended for ophthalmic-adjacent areas (masques, masques pour les yeux) must control irradiance carefully to remain within retinal blue-light safety thresholds defined by IEC 62471.
590 nm — Yellow (Pigmentation, Éclaircissement, Rougeur)
Yellow light at 590 nm is absorbed by hemoglobin and is widely used for reducing post-inflammatory erythema, diffuse redness, and minor pigmentation irregularities. It also has a documented role in calming sensitized skin post-procedure and is frequently incorporated into PDT (thérapie photodynamique) protocols for actinic keratosis as a supplemental wavelength.7
633 nm — Red (Collagène, Skin Rejuvenation)
633 nm is the most extensively studied wavelength in LED dermatology. Weiss et al. demonstrated that 633 nm LED photomodulation upregulates fibroblast activity and pro-collagen synthesis while simultaneously reducing matrix metalloproteinase-1 (MMP-1) expression — the enzyme responsible for collagen degradation.8 This dual mechanism is the basis for nearly every “anti-aging” claim associated with red-light therapy.9
Pénétration: ~ 2–3 mm (reticular dermis).
660 nm — Red (Soulagement de la douleur, Wound Healing)
660 nm shares many of 633 nm’s effects but penetrates slightly deeper and is more frequently cited in wound-healing and musculoskeletal pain literature. In vitro studies show 660 nm modulates fibroblast proliferation and influences ROS signaling at clinically relevant fluences.10 Most modern panel and belt-format devices combine 660 nm with an NIR wavelength such as 850 nm to address both superficial and deep tissue layers in a single session.
810 nm — Near-Infrared (Croissance des cheveux, Récupération)
810 nm penetrates beyond the dermis into the subcutaneous layer and is widely used in low-level laser therapy (Lllt) protocols for trauma recovery, neural modulation, and follicle stimulation. It is one of the standard wavelengths for transcranial photobiomodulation research as well.
830 nm — Near-Infrared (Tissue Healing, Bone Repair)
830 nm has documented effects on osteoblast activity, lymphatic drainage, and post-surgical recovery. It is the wavelength most frequently cited in peri-operative LED protocols used in plastic surgery clinics for bruise reduction and accelerated wound closure.
850 nm — Near-Infrared (Anti-âge, Muscle Recovery)
850 nm is the most popular NIR wavelength in consumer red-light panels because of its favorable balance between penetration depth (~5–6 mm into subcutaneous tissue) and LED efficiency at the chip level. Wunsch and Matuschka’s controlled trial demonstrated measurable improvements in skin roughness, wrinkle depth, and intradermal collagen density when 850 nm was combined with red wavelengths in a polychromatic protocol.11
1064 nm — Deep Infrared (Pigment, Adipose Modulation)
1064 nm reaches the deepest of any non-thermal LED wavelength in clinical use and is associated with adipose modulation and selective pigment targeting in laser-based protocols. In LED format (non-coherent), 1064 nm is used at lower irradiance for general deep-tissue conditioning.
1072 nm — Deep Infrared (Skin Barrier, Anti-Wrinkle)
1072 nm has a specific research footprint in herpes simplex management and skin-barrier recovery. It is one of the more specialized wavelengths and is generally configured into multi-wavelength professional systems rather than single-wavelength consumer devices.
3. Why Multi-Wavelength Devices Outperform Single-Wavelength Devices
UN 2008 study by Sadick demonstrated that combining red and infrared wavelengths produces measurably greater improvements in fine lines and skin texture than either wavelength alone.12 This is consistent with the broader photobiomodulation literature: different wavelengths reach different tissue depths and activate different chromophores, so a polychromatic protocol covers more biological ground per session.13
Cependant, “more wavelengths” is not automatically better. Three engineering trade-offs apply:
- Total irradiance must remain within safe and effective ranges — typically 30–100 mW/cm² at the skin surface.
- Each wavelength must deliver a clinically meaningful dose — adding a token number of LEDs at a “bonus” wavelength rarely produces the dose required for biological effect.
- Driver and thermal architecture must support the configuration — multi-wavelength devices require independent channel control to avoid mixing wavelengths into ineffective averages.
This is why two devices marketed with identical wavelength labels can produce very different clinical outcomes. Spec-sheet parity is not the same as performance parity.
4. Profondeur de pénétration: A Practical Reference
| Longueur d'onde | Approximate Penetration Depth | Primary Target Layer |
|---|---|---|
| 415 nm | ~1 mm | Épiderme |
| 460 nm | ~1–1.5 mm | Épiderme |
| 590 nm | ~1.5–2 mm | Derme papillaire |
| 633 nm | ~ 2–3 mm | Derme réticulaire |
| 660 nm | ~3 mm | Derme réticulaire |
| 810 nm | ~4–5 mm | Sous-cutané |
| 830 nm | ~5mm | Sous-cutané |
| 850 nm | ~5–6 mm | Sous-cutané |
| 1064 nm | ~6–8 mm | Deep subcutaneous |
| 1072 nm | ~6–8 mm | Deep subcutaneous |
Penetration values are approximate and depend on skin type, hydratation, irradiance, and beam geometry.2
5. Irradiance, Dose, and the Biphasic Curve
Wavelength alone does not determine outcome. Two additional parameters carry equal weight:
- Irradiance (MW / CM²) — the power density at the skin surface. Most clinical LED protocols operate between 30 et 100 MW / CM². Wakelife’s mainstream LED face masks deliver 60+ mW/cm² at the skin-facing surface, measured at calibrated working distance.
- Maîtrise (J/cm²) — the total energy delivered per unit area, calculated as irradiance × time. Most published protocols cluster between 3 et 60 J/cm² depending on indication and target depth.
Le dose-réponse biphasique described by Hamblin and others means that doubling exposure time does not double the result.14 Beyond an optimal window, additional exposure can suppress the very pathway the treatment is intended to activate. This is why responsible device design includes built-in timers and irradiance ceilings rather than open-ended “more is better” controls.
6. Clinical Indications and Wavelength Selection Logic
| Indication | Longueur d'onde primaire | Adjunct Wavelength |
|---|---|---|
| Inflammatory acne | 415 nm | 633 nm |
| Préchauffage / ridules | 633 nm | 850 nm |
| Post-procedure erythema | 590 nm | 633 nm |
| Pigmentation irregularities | 590 nm | 633 nm |
| Guérison des plaies | 660 nm | 830 nm |
| Repousse des cheveux | 650 nm | 850 nm |
| Joint and muscle recovery | 660 nm | 850 nm |
| Periorbital fine lines | 633 nm | 850 nm |
This matrix is not a treatment protocol — it is a wavelength-to-indication map for product planning. Final clinical protocols should always be validated against published evidence and, where applicable, regulatory clearance scope.
7. What FDA 510(k) Clearance Actually Means
FDA 510(k) clearance is a premarket submission demonstrating that a device is substantiellement équivalent à un dispositif principal commercialisé légalement. It is not a proof of efficacy in the colloquial sense — it is a regulatory finding that the device is as safe and as effective as its predicate for the cleared indication.
For LED phototherapy devices, the indications cleared under 510(k) typically fall within product code NHN (infrared lamp for medical purposes) ou ILY (powered light-based laser surgical instrument), depending on the device classification.
A representative recent clearance — FDA 510(k) K250830 — illustrates the structure of an LED face mask submission: defined wavelengths, defined irradiance ranges, defined treatment durations, and a labeled indication consistent with the predicate. Brands sourcing OEM/ODM products should verify three points before relying on a clearance:
- The clearance holder of record — the legal manufacturer named in the 510(k) is the entity FDA holds responsible. OEM customers receive a separately structured supply relationship that must be documented.
- The cleared indication for use — marketing claims must remain within the cleared indication. Off-label claims (Par exemple, “treats rosacea” when only “general dermatologic conditions” was cleared) create regulatory exposure.
- The configuration tested — wavelength count, Comptage des LED, irradiance, and treatment time submitted in the 510(k) define the cleared device. Material changes may require a new 510(k) under FDA’s 2017 guidance.16 17
It is also worth noting that effective February 2026, FDA’s Quality Management System Regulation (QMSR) will replace the legacy 21 CFR Part 820, harmonizing US requirements with ISO 13485.15 Manufacturers already operating under ISO 13485 (Wakelife included) are structurally positioned for this transition.
8. From Specification to Production: What Brands Should Verify
Before approving an OEM/ODM project for production, brands should request — and review — the following documentation:
- Spectral measurement reports — peak wavelength, full-width-at-half-maximum (FWHM), and spectral purity per LED bin.
- Photometric reports — irradiance at working distance, uniformity across the treatment surface, and beam angle.
- Photobiological safety reports — IEC 62471 risk group classification, particularly for blue-wavelength devices.
- EMC and electrical safety reports — IEC 60601-1 Et IEC 60601-1-2 for medical-grade devices, IEC 62368-1 for consumer-grade devices.
- Biocompatibility reports -ISO 10993 for any skin-contact materials, especially silicone face masks.
- Quality system documentation -ISO 13485 certification scope and applicable MDSAP coverage.
Wakelife provides each of these reports as standard deliverables for OEM/ODM partners, alongside the device itself. This is the documentation layer that distinguishes a regulated manufacturing partner from a generic supplier.
9. Résumé: A Working Framework for Wavelength Decisions
When evaluating an LED therapy product — whether sourcing for a brand, specifying for a clinic, or designing a new device — apply this five-step framework:
- Define the clinical objective first. Wavelength follows indication, not the reverse.
- Select wavelengths with peer-reviewed evidence at the target tissue depth. Penetration depth must match the layer where the chromophore lives.
- Verify irradiance and fluence at the skin-facing surface. “Number of LEDs” alone is not a performance metric.
- Confirm regulatory scope matches marketing claims. Cleared indication, not aspirational copy, defines what can lawfully be said.
- Require complete documentation from the manufacturer. Spectral, photometric, photobiological, EMC, and biocompatibility reports are non-negotiable.
Applied consistently, this framework separates evidence-based products from marketing-grade products and protects both end users and the brands that serve them.
10. À propos de Wakelife
Wakelife is the professional beauty division of Shenzhen Sungrow LED Technology Co., Ltd., a dedicated red-light therapy manufacturer founded in 2015. Operating from two ISO 13485 and MDSAP certified facilities totaling 20,000 m² in Shenzhen, Wakelife develops and produces LED face masks, red-light panels, Systèmes PDT, masques pour les yeux, hair-growth devices, targeted-care devices, ped red light therapy devices and therapy belts for professional beauty brands across more than 100 pays.
For technical specifications, photometric reports, or OEM/ODM inquiries, voir notre manufacturing and R&Capacités D or contact our engineering team directly. Additional Wakelife product information across all 9 LED therapy product lines is available on our product overview page.
Références
1. Karu TI. Signalisation mitochondriale dans les cellules de mammifères activée par le rayonnement rouge et proche IR. Photochem Photobiol. 2008;84(5):1091-1099.
2. Ash C, Dubec M, Donne K, Bashford T. Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. Lasers Med Sci. 2017;32(8):1909-1918.
3. Ashkenazi H, Malik Z, Harth Y, Nitzan Y. Eradication of Propionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light. FEMS Immunol Med Microbiol. 2003;35(1):17-24.
4. Goldberg DJ, Russell BA. Combination blue (415 nm) and red (633 nm) LED phototherapy in the treatment of mild to severe acne vulgaris. J Cosmet Laser Ther. 2006;8(2):71-75.
5. Lee SY, You CE, Park MY. Blue and red light combination LED phototherapy for acne vulgaris in patients with skin phototype IV. Lasers Surg Med. 2007;39(2):180-188.
6. Scott AM, Stehlik P, Clark J, et autres. Blue-light therapy for acne vulgaris: a systematic review and meta-analysis. Ann Fam Med. 2019;17(6):545-553.
7. Opel DR, Hagstrom E, Pace AK, et autres. Diodes électroluminescentes: A brief review and clinical experience. J Clin Aesthet Dermatol. 2015;8(6):36-44.
8. Weiss RA, McDaniel DH, Geronemus RG, Weiss MA. Clinical experience with light-emitting diode (DIRIGÉ) photomodulation. Dermatol Surg. 2005;31(9 Pt 2):1199-1205.
9. Barolet D. Diodes électroluminescentes (LEDS) en dermatologie. Chirurgie médicale semi-coupée. 2008;27(4):227-238.
10. Lev-Tov H, Mamalis A, Brody N, Siegel D, Jagdeo J. Inhibition of fibroblast proliferation in vitro using red light-emitting diodes. Dermatol Surg. 2013;39(8):1167-1170.
11. Souhait A, Matuschka K.. Un essai contrôlé pour déterminer l'efficacité du traitement par la lumière rouge et proche infrarouge sur la satisfaction des patients, réduction des ridules, rides, rugosité de la peau, et augmentation de la densité intradermique du collagène. Photomed Laser Surg. 2014;32(2):93-100.
12. Sadick NS. A study to determine the efficacy of a novel handheld light-emitting diode device in the treatment of photoaged skin. J Cosmet Dermatol. 2008;7(4):263-267.
13. Avc P, Gupta A., Sadasivam M, et autres. Laser de bas niveau (lumière) thérapie (Lllt) dans la peau: stimulant, guérison, restauration. Chirurgie médicale semi-coupée. 2013;32(1):41-52.
14. Hamblin MR. Mécanismes et applications des effets anti-inflammatoires de la photobiomodulation. AIMS Biophys. 2017;4(3):337-361.
15. NOUS. Food and Drug Administration. Medical Devices; Quality System Regulation Amendments (QMSR Final Rule), 89 FR 7496. Effective February 2, 2026.
16. NOUS. Food and Drug Administration. Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and FDA Staff. October 25, 2017.
17. NOUS. Food and Drug Administration. Deciding When to Submit a 510(k) for a Software Change to an Existing Device — Guidance for Industry and FDA Staff. October 25, 2017.
